X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Immedica gains global rights of AEB1102 (pegzilarginase), a novel recombinant human enzyme engineered to degrade the amino acid arginine, for the treatment of rare metabolic disease Arginase 1 Deficiency.
Lead Product(s): Pegzilarginase
Therapeutic Area: Genetic Disease Product Name: AEB1102
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immedica Pharma
Deal Size: $115.0 million Upfront Cash: $15.0 million
Deal Type: Agreement July 27, 2023
Details:
Through the acquisition, Aeglea expands its inflammatory bowel disease portfolio by including, SPY001 and SPY002, that are potentially best-in-class antibodies targeting a 4 b 7 and TL1A, respectively.
Lead Product(s): SPY001
Therapeutic Area: Gastroenterology Product Name: SPY001
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Spyre Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 22, 2023
Details:
The company intends to use the net proceeds in advancing a leading inflammatory bowel disease (IBD) portfolio including, SPY001 and SPY002, that are potentially best-in-class antibodies targeting a 4 b 7 and TL1A, respectively.
Lead Product(s): SPY001
Therapeutic Area: Gastroenterology Product Name: SPY001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fairmount Funds Management
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 22, 2023
Details:
ACN00177 (pegtarviliase) is a novel recombinant human enzyme engineered to reduce elevated levels of total homocysteine, for the treatment of classical homocystinuria.
Lead Product(s): Pegtarviliase
Therapeutic Area: Genetic Disease Product Name: ACN00177
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
AEB1102 (pegzilarginase) is a novel, recombinant human arginase 1 enzyme that in clinical trials has been shown to normalize the elevated levels of the amino acid arginine in patients with ARG1-D, a rare, progressive disease characterized by high levels of arginine.
Lead Product(s): Pegzilarginase
Therapeutic Area: Genetic Disease Product Name: AEB1102
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
In PEACE Phase 3 clinical trial, treatment with pegzilarginase was shown to markedly reduce blood arginine levels in patients with ARG1-D, also has received several regulatory designations from the U.S.FDA as well as Orphan drug designation from the EMA.
Lead Product(s): Pegzilarginase
Therapeutic Area: Genetic Disease Product Name: AEB1102
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Pegzilarginase met its primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment is a First potential therapy to address key driver of ARG1-D, a devastating ultra-rare disease.
Lead Product(s): Pegzilarginase
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Details:
Result showed Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment.
Lead Product(s): Pegzilarginase
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2021
Details:
Aeglea BioTherapeutics has completed patient randomization for PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), the pivotal Phase 3 clinical trial investigating pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).
Lead Product(s): Pegzilarginase
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Details:
Aeglea BioTherapeutics will supply pegzilarginase, a novel, recombinant human arginase 1 enzyme that has been shown to lower toxic levels of the amino acid arginine in patients with Arginase 1 Deficiency (ARG1-D).
Lead Product(s): Pegzilarginase
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immedica
Deal Size: $151.5 million Upfront Cash: $21.5 million
Deal Type: Licensing Agreement March 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
